Cargando…
Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients
PURPOSE: Molecular characteristics using gene-expression profiling can undoubtedly improve the prediction of treatment responses, and ultimately, the clinical outcome of cancer patients. We aimed at developing a genetic signature to improve the prediction of chemosensitivity and prognosis of patient...
Autores principales: | Li, Jianxia, Zhang, Jianwei, Hu, Huabin, Cai, Yue, Ling, Jiayu, Wu, Zehua, Deng, Yanhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227814/ https://www.ncbi.nlm.nih.gov/pubmed/32494194 http://dx.doi.org/10.2147/CMAR.S243490 |
Ejemplares similares
-
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020) -
Identification of immune cell infiltration landscape for predicting prognosis of colorectal cancer
por: Wu, Xueqian, et al.
Publicado: (2023) -
Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023) -
Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence – A retrospective single-center study
por: Deng, Yanhong, et al.
Publicado: (2015) -
The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy
por: Wu, Zehua, et al.
Publicado: (2022)